Sanofi CEO's strategy blueprint may include consumer health spinoff or merger: Bloomberg

Sanofi CEO Paul Hudson
Paul Hudson joined Sanofi from Novartis and started as CEO Sept. 1. (Sanofi)

Sanofi CEO Paul Hudson has been on the job for just over two months, and he's prepping for a big strategy reveal next month. One thing that might be behind that curtain? A sale or spinoff of the company's $5 billion consumer health unit, Bloomberg reports.

Hudson, who took the reins at Sanofi Sept. 1, may choose to spin the unit out or merge it with another company’s outfit, according to the news service, which cites people familiar with the deliberations. 

The company hasn't decided for sure, Bloomberg says. And according to Sanofi, Hudson is looking at options across the entire company ahead of Capital Markets Day Dec. 10, when he'll outline his plans for the French drugmaker.

"In preparation for this, all of our businesses are undergoing thorough reviews," a Sanofi spokesperson said.

It'll be the first detailed look at Hudson's thinking. The former Novartis exec has talked only in general terms about his plans; instead, he’s been on a “listening tour,” visiting Sanofi operations around the world. He’s reviewing all of the company’s businesses—even diabetes, where the drugmaker has an established history but has faced challenges lately.  

RELATED: CEO Paul Hudson's turning 'clear eyes' on Sanofi—and hinting at changes ahead 

If the drugmaker does exit consumer healthcare, it wouldn’t be alone. GlaxoSmithKline and Pfizer this year combined their consumer health outfits in a massive joint venture, and within three years, GSK plans to spin the company out as a standalone company. 

Novartis previously sold its stake in a consumer healthcare JV back to GSK. The drugmaker also spun off its Alcon eyecare unit. And outside its consumer healthcare deal with GSK, Pfizer recently inked an agreement to merge its off-patent drugs business with Mylan to create a new company that'll be called Viatris.  

All of the moves are designed to help the pharma giants focus on innovative medicines at a time when drugmakers face a pricing squeeze, a battered reputation, political pressure and more.  

RELATED: Will pharma's exodus from consumer health continue into 2019? It sure looks that way 

Sanofi has already made steps to focus on innovative meds. The company's former CEO Olivier Brandicourt last year inked buyouts of rare disease biotechs in 2018, picking up hemophilia-focused Bioverativ and nanobody biotech Ablynx in quick succession to start the year. 

Suggested Articles

Besides paying $729 million to settle notorious kickback allegations, Novartis has promised to put strict restrictions on its future speaker programs.

Pharma companies including Pfizer and Novartis paused advertising on Facebook for July to protest hate and disinformation on the platform.

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.